Main Article Content
Purpose: The purpose of this study was to investigate the treatment outcomes of secondary glaucoma caused by cytomegalovirus (CMV)-anterior uveitis (AU) with continuous 0.5% ganciclovir eye drop.
Study Design: Retrospective observational study.
Place and Duration of Study: Department of Ophthalmology, Oita University Hospital, between January 2012 and December 2017.
Methodology: Nineteen eyes of 19 patients with secondary glaucoma associated with CMV-AU diagnosed by a polymerase chain reaction analysis from human aqueous samples were enrolled. They were treated with continuous 4-times-daily topical 0.5% ganciclovir in addition to topical steroids and anti-glaucoma medications. We performed glaucoma surgery for patients with poorly medically controlled intraocular pressure (IOP).
Results: Anterior chamber inflammation and IOP were controlled without systemic ganciclovir or glaucoma surgery during the follow-up period (mean: 59.2±27.0 months) in 9 (47%) eyes. Five (26%) eyes required systemic ganciclovir and ten (53%) eyes required glaucoma surgery. Patients were divided into two groups for the comparison: one group requiring glaucoma surgery and one treated with medication. The mean IOP and number of anti-glaucoma medications at the first visit were significantly higher in the surgery group than in the medication group. The mean number of IOP spikes per year (IOP >30 mmHg) was 1.4±0.9 in the surgery group and 0.4±0.5 in the medication group. The recurrence of anterior chamber inflammation was suppressed in both groups. The cumulative survival rate after glaucoma surgery was 80% at 12 months and 70% at 36 months.
Conclusion: The anterior chamber inflammation and IOP were controlled with continuous 0.5% ganciclovir eye drop treatment in half of the patients with CNV-AU. A high IOP at the first visit and frequent IOP spikes were risk factors for additional glaucoma surgeries.Cytomegalovirus
Van Boxtel LA, Van Der Lelij A, Van Der Meer J, Los LI. Cytomegalovirus as a cause of anterior uveitis in immuno competent patients. Ophthalmology. 2007; 114:1358–62.
Wong JX, Wong EP, Teoh SC. Outcomes of cytomegalovirus retinitis-related retinal detachment surgery in acquired immunodeficiency syndrome patients in an Asian population. BMC Ophthalmol. 2014; 14:150.
Available:https:// doi: 10.1186/1471-2415-14-150.
Chee SP, Bacsal K, Jap A, Se-Thoe SY, Cheng CL, Tan BH. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. Am J Ophthalmol. 2008;145:834–40.
Accorinti M, Gilardi M, Pirraglia MP, Amorelli GM, Nardella C, Abicca I, et al. Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients. Graefes Arch Clin Exp Ophthalmol. 2014;252:1817-24.
Takase H, Kubono R, Terada Y, Imai A, Fukuda S, Tomita M, et al. Comparison of the ocular characteristics of anterior uveitis caused by herpes simplex virus, varicella-zoster virus, and cytomegalovirus. Jpn J Ophthalmol. 2014;58:473–82.
Shirahama S, Kaburaki T, Takada S, Nakahara H, Tanaka R, Komae K, et al. Comparison of visual field defect progression in secondary glaucoma due to anterior uveitis caused by three types of herpes viruses. Graefes Arch Clin Exp Ophthalmol. 2020;258:639–45.
De Groot-Mijnes JD, Rothova A, Van Loon AM, Schuller M, Ten Dam-Van Loon NH, De Boer JH, et al. Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J Ophthalmol. 2006;141:313-8.
Shoughy SS, Alkatan HM, Al-Abdullah AA, El-Khani A, De Groot-Mijnes JD, Tabbara KF. Polymerase chain reaction in unilateral cases of presumed viral anterior uveitis. Clin Ophthalmol.2015;9:2325-8.
Yamamoto S, Pavan-Langston D, Kinoshita S, Nishida K, Shimomura Y, Tano Y. Detecting herpesvirus DNA in uveitis using the polymerase chain reaction. Br J Ophthalmology. 1996;80:465-8.
Nakano S, Sugita S, Tomaru Y, Hono A, Nakamuro T, Kubota T, et al. Establishment of multiplex solid-phase strip PCR Test for detection of 24 ocular infectious disease pathogens. Invest Ophthalmol Vis Sci.2017;58:1553-9.
Maruyama K, Maruyama Y, Sugita S, Mori K, Yokoyama Y, Sanuki-Kunimatsu S, et al. Characteristics of cases needing advanced treatment for intractable posner–schlossman syndrome. BMC Ophthalmology. 2017;17:45.
Villarreal EC. Current and potential therapies for the treatment of herpes-virus infections. Prog Drug Res. 2003;60:263–307.
Su CC, Hu FR,Wang TH, Huang JY,Yeh PT, Lin CP, et al. Clinical outcomes in cytomegalovirus-positive posner-schlossman syndrome patients treated with topical ganciclovir therapy. Am J Ophthalmol. 2014;158:1024–31.
Koizumi N, Miyazaki D, Inoue T, Ohtani F, Kandori-Inoue M, Inatomi T, et al.The effect of topical application of 0.15% ganciclovir gel on Cytomegalovirus corneal endotheliitis. Br J Ophthalmol. 2016; 101:114-9.
Chee SP, Jap A. Cytomegalovirus anterior uveitis: outcome of treatment. Br J Ophthalmol. 2010;94:1648–52.
Wong JX, Agrawal R, Wong EP, Teoh SC. Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis. J Ophthalmic Inflamm Infect. 2016;6(1): 10.
Avaliable:https:// doi: 10.1186/s12348-016-0078-z
Keorochana N, Choontanom R. Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis. BMJ Open Ophthalmol.2017;2:000061.
Available:https:// doi: 10.1136/bmjophth-2016-000061
Choi JA, Kim JE, Noh SJ, Kim EK, Park CK, Paik SY. Enhanced Cytomegalovirus infection in human trabecular meshwork cells and its implication in glaucoma pathogenesis. Scientific Reoprts. 2017; 7:43349.
Available:https:// doi: 10.1038/srep43349
Iverson SM, Bhardwaj N, Shi W, Sehi M, Greenfield DS, Budenz DL, et al. Surgical outcomes of inflammatory glaucoma: a comparison of trabeculectomy and glaucoma-drainage-device implantation. Jpn J Ophthalmol.2015;59:179-86.
You YA, Wu Y, Hu S. Surgical management of secondary glaucoma in fuchs' heterochromic iridocyclitis. Graefes Arch Clin Exp Ophthalmol. 2013;251: 1785-90.